{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T10:08:23Z","timestamp":1775902103562,"version":"3.50.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T00:00:00Z","timestamp":1575590400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T00:00:00Z","timestamp":1575590400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologe"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s00347-019-01021-4","type":"journal-article","created":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T17:03:03Z","timestamp":1575651783000},"page":"113-123","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Alternative Behandlungsoptionen beim Basalzellkarzinom am Auge","Alternative treatment options for periorbital basal cell carcinoma"],"prefix":"10.1007","volume":"117","author":[{"given":"Vinodh","family":"Kakkassery","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffen","family":"Emmert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iren\u00e4us A.","family":"Adamietz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gy\u00f6rgy","family":"Kov\u00e1cs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anselm M.","family":"J\u00fcnemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Otte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Zimbelmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anton","family":"Brosig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Grisanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludwig M.","family":"Heindl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,6]]},"reference":[{"issue":"2","key":"1021_CR1","first-page":"214","volume":"17","author":"BM Lang","year":"2019","unstructured":"Lang\u00a0BM, Balermpas\u00a0P, Bauer\u00a0A, Blum\u00a0A, Brolsch\u00a0GF, Dirschka\u00a0T et al (2019) S2k-Leitlinie Basalzellkarzinom der Haut \u2013 Teil 2: Therapie, Pravention und Nachsorge. J\u00a0Dtsch Dermatol Ges 17(2):214\u2013231","journal-title":"J Dtsch Dermatol Ges"},{"issue":"1","key":"1021_CR2","first-page":"94","volume":"17","author":"BM Lang","year":"2019","unstructured":"Lang\u00a0BM, Balermpas\u00a0P, Bauer\u00a0A, Blum\u00a0A, Brolsch\u00a0GF, Dirschka\u00a0T et al (2019) S2k-Leitlinie Basalzellkarzinom der Haut \u2013 Teil 1: Epidemiologie, Genetik und Diagnostik. J\u00a0Dtsch Dermatol Ges 17(1):94\u2013104","journal-title":"J Dtsch Dermatol Ges"},{"key":"1021_CR3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejca.2019.06.003","volume":"118","author":"K Peris","year":"2019","unstructured":"Peris\u00a0K, Fargnoli\u00a0MC, Garbe\u00a0C, Kaufmann\u00a0R, Bastholt\u00a0L, Seguin\u00a0NB et al (2019) Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines. Eur J Cancer 118:10\u201334","journal-title":"Eur J Cancer"},{"key":"1021_CR4","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.oraloncology.2017.07.018","volume":"72","author":"A Rishi","year":"2017","unstructured":"Rishi\u00a0A, Huang\u00a0HS, O\u2019Sullivan\u00a0B, Goldstein\u00a0DP, Lu\u00a0L, Ringash\u00a0J et\u00a0al (2017) Outcome following radiotherapy for head and neck basal cell carcinoma with \u201caggressive\u201d features. Oral Oncol 72:157\u2013164","journal-title":"Oral Oncol"},{"issue":"3","key":"1021_CR5","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1177\/1203475416687268","volume":"21","author":"CW Duinkerken","year":"2017","unstructured":"Duinkerken\u00a0CW, Lohuis\u00a0P, Crijns\u00a0MB, Navran\u00a0A, Haas\u00a0RLM, Hamming-Vrieze\u00a0O et al (2017) Orthovoltage X\u2011rays for postoperative treatment of resected basal cell carcinoma in the head and neck area. J\u00a0Cutan Med Surg 21(3):243\u2013249","journal-title":"J Cutan Med Surg"},{"issue":"8","key":"1021_CR6","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1002\/lary.25865","volume":"126","author":"CW Duinkerken","year":"2016","unstructured":"Duinkerken\u00a0CW, Lohuis\u00a0PJ, Heemsbergen\u00a0WD, Zupan-Kajcovski\u00a0B, Navran\u00a0A, Hamming-Vrieze\u00a0O et al (2016) Orthovoltage for basal cell carcinoma of the head and neck: excellent local control and low toxicity profile. Laryngoscope 126(8):1796\u20131802","journal-title":"Laryngoscope"},{"issue":"1","key":"1021_CR7","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5114\/jcb.2016.57531","volume":"8","author":"R Ballester-Sanchez","year":"2016","unstructured":"Ballester-Sanchez\u00a0R, Pons-Llanas\u00a0O, Candela-Juan\u00a0C, Celada-Alvarez\u00a0FJ, Barker\u00a0CA, Tormo-Mico\u00a0A et al (2016) Electronic brachytherapy for superficial and nodular basal cell carcinoma: a\u00a0report of two prospective pilot trials using different doses. J\u00a0Contemp Brachytherapy 8(1):48\u201355","journal-title":"J Contemp Brachytherapy"},{"issue":"3","key":"1021_CR8","doi-asserted-by":"crossref","first-page":"231","DOI":"10.5114\/jcb.2015.52140","volume":"7","author":"R Ballester-Sanchez","year":"2015","unstructured":"Ballester-Sanchez\u00a0R, Pons-Llanas\u00a0O, Candela-Juan\u00a0C, Celada-Alvarez\u00a0FJ, de Unamuno-Bustos\u00a0B, Llavador-Ros\u00a0M et al (2015) Efficacy and safety of electronic brachytherapy for superficial and nodular basal cell carcinoma. J\u00a0Contemp Brachytherapy 7(3):231\u2013238","journal-title":"J Contemp Brachytherapy"},{"issue":"6","key":"1021_CR9","doi-asserted-by":"crossref","first-page":"533","DOI":"10.5114\/jcb.2016.64112","volume":"8","author":"D Delishaj","year":"2016","unstructured":"Delishaj\u00a0D, Rembielak\u00a0A, Manfredi\u00a0B, Ursino\u00a0S, Pasqualetti\u00a0F, Laliscia\u00a0C et al (2016) Non-melanoma skin cancer treated with high-dose-rate brachytherapy: a\u00a0review of literature. J\u00a0Contemp Brachytherapy 8(6):533\u2013540","journal-title":"J Contemp Brachytherapy"},{"issue":"5","key":"1021_CR10","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1080\/09546634.2016.1274365","volume":"28","author":"R Piccinno","year":"2017","unstructured":"Piccinno\u00a0R, Benardon\u00a0S, Gaiani\u00a0FM, Rozza\u00a0M, Caccialanza\u00a0M (2017) Dermatologic radiotherapy in the treatment of extensive basal cell carcinomas: a\u00a0retrospective study. J\u00a0Dermatolog Treat 28(5):426\u2013430","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"1021_CR11","doi-asserted-by":"crossref","first-page":"437","DOI":"10.5114\/jcb.2015.55746","volume":"7","author":"D Delishaj","year":"2015","unstructured":"Delishaj\u00a0D, Laliscia\u00a0C, Manfredi\u00a0B, Ursino\u00a0S, Pasqualetti\u00a0F, Lombardo\u00a0E et al (2015) Non-melanoma skin cancer treated with high-dose-rate brachytherapy and Valencia applicator in elderly patients: a\u00a0retrospective case series. J\u00a0Contemp Brachytherapy 7(6):437\u2013444","journal-title":"J Contemp Brachytherapy"},{"key":"1021_CR12","doi-asserted-by":"crossref","first-page":"825","DOI":"10.21873\/anticanres.11384","volume":"37(2","author":"M Valeriani","year":"2017","unstructured":"Valeriani\u00a0M, Nicosia\u00a0L, Agolli\u00a0L, Reverberi\u00a0C, Galvagno\u00a0E et al (2017) Mono- and Bi-weekly hypofractionated radiation therapy for the treatment of epithelial skin cancer in very elderly patients. Anticancer Res 37(2:825\u2013830","journal-title":"Anticancer Res"},{"issue":"3","key":"1021_CR13","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1524-4725.1989.tb03166.x","volume":"15","author":"DE Rowe","year":"1989","unstructured":"Rowe\u00a0DE, Carroll\u00a0RJ, Day\u00a0CL Jr. (1989) Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J\u00a0Dermatol Surg Oncol 15(3):315\u2013328","journal-title":"J Dermatol Surg Oncol"},{"issue":"2","key":"1021_CR14","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/jdv.12076","volume":"28","author":"SR Wiegell","year":"2014","unstructured":"Wiegell\u00a0SR, Skodt\u00a0V, Wulf\u00a0HC (2014) Daylight-mediated photodynamic therapy of basal cell carcinomas\u2014an explorative study. J\u00a0Eur Acad Dermatol Venereol 28(2):169\u2013175","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1021_CR15","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0360-3016(90)90529-S","volume":"19","author":"RD Lovett","year":"1990","unstructured":"Lovett\u00a0RD, Perez\u00a0CA, Shapiro\u00a0SJ, Garcia\u00a0DM (1990) External irradiation of epithelial skin cancer. Int J Radiat Oncol Biol Phys 19(2):235\u2013242","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"5","key":"1021_CR16","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/0360-3016(94)00603-I","volume":"32","author":"C Griep","year":"1995","unstructured":"Griep\u00a0C, Davelaar\u00a0J, Scholten\u00a0AN, Chin\u00a0A, Leer\u00a0JW (1995) Electron beam therapy is not inferior to superficial x\u2011ray therapy in the treatment of skin carcinoma. Int J Radiat Oncol Biol Phys 32(5):1347\u20131350","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"2","key":"1021_CR17","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jaad.2015.09.031","volume":"74","author":"R Pampena","year":"2016","unstructured":"Pampena\u00a0R, Palmieri\u00a0T, Kyrgidis\u00a0A, Ramundo\u00a0D, Iotti\u00a0C, Lallas\u00a0A et\u00a0al (2016) Orthovoltage radiotherapy for nonmelanoma skin cancer (NMSC): comparison between 2 different schedules. J\u00a0Am Acad Dermatol 74(2):341\u2013347","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1021_CR18","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/bjc.1997.343","volume":"76","author":"MF Avril","year":"1997","unstructured":"Avril\u00a0MF, Auperin\u00a0A, Margulis\u00a0A, Gerbaulet\u00a0A, Duvillard\u00a0P, Benhamou\u00a0E et\u00a0al (1997) Basal cell carcinoma of the face: surgery or radiotherapy? Results of a\u00a0randomized study. Br J Cancer 76(1):100\u2013106","journal-title":"Br J Cancer"},{"issue":"Suppl 3:10\u20135","key":"1021_CR19","first-page":"1","volume":"11","author":"A Hauschild","year":"2013","unstructured":"Hauschild\u00a0A, Breuninger\u00a0H, Kaufmann\u00a0R, Kortmann\u00a0RD, Klein\u00a0M, Werner\u00a0J et\u00a0al (2013) Brief S2k guidelines\u2014basal cell carcinoma of the skin. J\u00a0Dtsch Dermatol Ges 11(Suppl 3:10\u20135):1\u20136","journal-title":"J Dtsch Dermatol Ges"},{"issue":"3","key":"1021_CR20","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.ijrobp.2005.03.027","volume":"63","author":"E Rio","year":"2005","unstructured":"Rio\u00a0E, Bardet\u00a0E, Ferron\u00a0C, Peuvrel\u00a0P, Supiot\u00a0S, Campion\u00a0L et\u00a0al (2005) Interstitial brachytherapy of periorificial skin carcinomas of the face: a\u00a0retrospective study of 97 cases. Int J Radiat Oncol Biol Phys 63(3):753\u2013757","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"22","key":"1021_CR21","first-page":"389","volume":"111","author":"C Berking","year":"2014","unstructured":"Berking\u00a0C, Hauschild\u00a0A, Kolbl\u00a0O, Mast\u00a0G, Gutzmer\u00a0R (2014) Basal cell carcinoma-treatments for the commonest skin cancer. Dtsch Arztebl Int 111(22):389\u2013395","journal-title":"Dtsch Arztebl Int"},{"issue":"5","key":"1021_CR22","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/bjd.13253","volume":"171","author":"M Cho","year":"2014","unstructured":"Cho\u00a0M, Gordon\u00a0L, Rembielak\u00a0A, Woo\u00a0TC (2014) Utility of radiotherapy for treatment of basal cell carcinoma: a\u00a0review. Br J Dermatol 171(5):968\u2013973","journal-title":"Br J Dermatol"},{"issue":"1","key":"1021_CR23","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0360-3016(91)90171-Y","volume":"21","author":"B Emami","year":"1991","unstructured":"Emami\u00a0B, Lyman\u00a0J, Brown\u00a0A, Coia\u00a0L, Goitein\u00a0M, Munzenrider\u00a0JE et\u00a0al (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21(1):109\u2013122","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"3 Suppl","key":"1021_CR24","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.ijrobp.2009.07.1754","volume":"76","author":"LB Marks","year":"2010","unstructured":"Marks\u00a0LB, Yorke\u00a0ED, Jackson\u00a0A, Ten Haken\u00a0RK, Constine\u00a0LS, Eisbruch\u00a0A et\u00a0al (2010) Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys 76(3 Suppl):S10\u2013S19","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1056","key":"1021_CR25","doi-asserted-by":"crossref","first-page":"20150405","DOI":"10.1259\/bjr.20150405","volume":"88","author":"SR McKeown","year":"2015","unstructured":"McKeown\u00a0SR, Hatfield\u00a0P, Prestwich\u00a0RJ, Shaffer\u00a0RE, Taylor\u00a0RE (2015) Radiotherapy for benign disease; assessing the risk of radiation-induced cancer following exposure to intermediate dose radiation. Br J Radiol 88(1056):20150405","journal-title":"Br J Radiol"},{"issue":"8","key":"1021_CR26","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.clon.2015.01.009","volume":"27","author":"RE Taylor","year":"2015","unstructured":"Taylor\u00a0RE, Hatfield\u00a0P, McKeown\u00a0SR, Prestwich\u00a0RJ, Shaffer\u00a0R (2015) Radiotherapy for benign disease: current evidence, benefits and risks. Clin Oncol 27(8):433\u2013435","journal-title":"Clin. Oncol."},{"issue":"7","key":"1021_CR27","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/hmg\/10.7.757","volume":"10","author":"AE Bale","year":"2001","unstructured":"Bale\u00a0AE, Yu\u00a0KP (2001) The hedgehog pathway and basal cell carcinomas. Hum Mol Genet 10(7):757\u2013762","journal-title":"Hum. Mol. Genet."},{"issue":"19","key":"1021_CR28","doi-asserted-by":"crossref","first-page":"8597","DOI":"10.1158\/0008-5472.CAN-05-0842","volume":"65","author":"MT Teh","year":"2005","unstructured":"Teh\u00a0MT, Blaydon\u00a0D, Chaplin\u00a0T, Foot\u00a0NJ, Skoulakis\u00a0S, Raghavan\u00a0M et\u00a0al (2005) Genomewide single nucleotide polymorphism microarray mapping in basal cell carcinomas unveils uniparental disomy as a\u00a0key somatic event. Cancer Res 65(19):8597\u20138603","journal-title":"Cancer Res"},{"issue":"3","key":"1021_CR29","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s00347-016-0370-1","volume":"114","author":"V Kakkassery","year":"2017","unstructured":"Kakkassery\u00a0V, Loeffler\u00a0KU, Sand\u00a0M, Koch\u00a0KR, Lentzsch\u00a0AM, Nick\u00a0AC et\u00a0al (2017) Current diagnostics and therapy recommendations for ocular basal cell carcinoma. Ophthalmologe 114(3):224\u2013236","journal-title":"Ophthalmologe"},{"key":"1021_CR30","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-120086","author":"V Kakkassery","year":"2017","unstructured":"Kakkassery\u00a0V, Heindl\u00a0LM (2017) SOP\u2014standarized procedures in diagnostics and therapies of periocular basal cell carcinoma. Klin Monbl Augenheilkd. https:\/\/doi.org\/10.1055\/s-0043-120086","journal-title":"Klin Monbl Augenheilkd"},{"key":"1021_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/s00347-019-00948-y","author":"AC Rokohl","year":"2019","unstructured":"Rokohl\u00a0AC, Loser\u00a0H, Mor\u00a0JM, Loreck\u00a0N, Koch\u00a0KR, Heindl\u00a0LM (2019) Young male patient with unusual space-occupying lesion of the lower eyelid. Ophthalmologe. https:\/\/doi.org\/10.1007\/s00347-019-00948-y","journal-title":"Ophthalmologe"},{"issue":"23","key":"1021_CR32","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1113713","volume":"366","author":"A Sekulic","year":"2012","unstructured":"Sekulic\u00a0A, Migden\u00a0MR, Oro\u00a0AE, Dirix\u00a0L, Lewis\u00a0KD, Hainsworth\u00a0JD et al (2012) Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 366(23):2171\u20132179","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"1021_CR33","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jaad.2015.03.021","volume":"72","author":"A Sekulic","year":"2015","unstructured":"Sekulic\u00a0A, Migden\u00a0MR, Lewis\u00a0K, Hainsworth\u00a0JD, Solomon\u00a0JA, Yoo\u00a0S et al (2015) Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J Am Acad Dermatol 72(6):1021\u20131026.e8","journal-title":"J. Am. Acad. Dermatol."},{"issue":"23","key":"1021_CR34","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1056\/NEJMoa1113538","volume":"366","author":"JY Tang","year":"2012","unstructured":"Tang\u00a0JY, Mackay-Wiggan\u00a0JM, Aszterbaum\u00a0M, Yauch\u00a0RL, Lindgren\u00a0J, Chang\u00a0K et al (2012) Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med 366(23):2180\u20132188","journal-title":"N. Engl. J. Med."},{"key":"1021_CR35","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ejca.2017.08.022","volume":"86","author":"N Basset-Seguin","year":"2017","unstructured":"Basset-Seguin\u00a0N, Hauschild\u00a0A, Kunstfeld\u00a0R, Grob\u00a0J, Dreno\u00a0B, Mortier\u00a0L et al (2017) Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial. Eur J Cancer 86:334\u2013348","journal-title":"Eur J Cancer"},{"issue":"6","key":"1021_CR36","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(15)70100-2","volume":"16","author":"MR Migden","year":"2015","unstructured":"Migden\u00a0MR, Guminski\u00a0A, Gutzmer\u00a0R, Dirix\u00a0L, Lewis\u00a0KD, Combemale\u00a0P et al (2015) Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a\u00a0multicentre, randomised, double-blind phase 2 trial. Lancet Oncol 16(6):716\u2013728","journal-title":"Lancet Oncol"},{"issue":"1","key":"1021_CR37","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jaad.2016.02.1226","volume":"75","author":"R Dummer","year":"2016","unstructured":"Dummer\u00a0R, Guminski\u00a0A, Gutzmer\u00a0R, Dirix\u00a0L, Lewis\u00a0KD, Combemale\u00a0P et al (2016) The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): a phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. J Am Acad Dermatol 75(1):113\u2013125.e5","journal-title":"J. Am. Acad. Dermatol."},{"issue":"12","key":"1021_CR38","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/jamaophthalmol.2013.5018","volume":"131","author":"HS Gill","year":"2013","unstructured":"Gill\u00a0HS, Moscato\u00a0EE, Chang\u00a0AL, Soon\u00a0S, Silkiss\u00a0RZ (2013) Vismodegib for periocular and orbital basal cell carcinoma. JAMA Ophthalmol 131(12):1591\u20131594","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"1021_CR39","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/IOP.0000000000000388","volume":"31","author":"H Demirci","year":"2015","unstructured":"Demirci\u00a0H, Worden\u00a0F, Nelson\u00a0CC, Elner\u00a0VM, Kahana\u00a0A (2015) Efficacy of vismodegib (erivedge) for basal cell carcinoma involving the orbit and periocular area. Ophthal Plast Reconstr Surg 31(6):463\u2013466","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"1021_CR40","doi-asserted-by":"publisher","DOI":"10.1097\/iop.0000000000000565","author":"VP Papastefanou","year":"2015","unstructured":"Papastefanou\u00a0VP, Rene\u00a0C (2015) Secondary resistance to vismodegib after initial successful treatment of extensive recurrent periocular basal cell carcinoma with orbital invasion. Ophthal Plast Reconstr Surg. https:\/\/doi.org\/10.1097\/iop.0000000000000565","journal-title":"Ophthal Plast Reconstr Surg"},{"issue":"2","key":"1021_CR41","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ajo.2015.04.040","volume":"160","author":"OK Ozgur","year":"2015","unstructured":"Ozgur\u00a0OK, Yin\u00a0V, Chou\u00a0E, Ball\u00a0S, Kies\u00a0M, William\u00a0WN et\u00a0al (2015) Hedgehog pathway inhibition for locally advanced periocular basal cell carcinoma and basal cell nevus syndrome. Am J Ophthalmol 160(2):220\u2013227.e2","journal-title":"Am. J. Ophthalmol."},{"issue":"3","key":"1021_CR42","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00347-018-0734-9","volume":"116","author":"B Lauterbach","year":"2019","unstructured":"Lauterbach\u00a0B, Kakkassery\u00a0V, Debus\u00a0D, Heindl\u00a0LM, Schultz\u00a0ES (2019) Advanced periocular basal cell carcinoma\u2014a therapeutic challenge. Ophthalmologe 116(3):273\u2013277","journal-title":"Ophthalmologe"},{"issue":"5","key":"1021_CR43","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.jaad.2014.05.020","volume":"71","author":"MS Ally","year":"2014","unstructured":"Ally\u00a0MS, Aasi\u00a0S, Wysong\u00a0A, Teng\u00a0C, Anderson\u00a0E, Bailey-Healy\u00a0I et al (2014) An investigator-initiated open-label clinical trial of vismodegib as a\u00a0neoadjuvant to surgery for high-risk basal cell carcinoma. J\u00a0Am Acad Dermatol 71(5):904\u20139011.e1","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1021_CR44","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/annonc\/mdv551","volume":"27","author":"M Sand","year":"2016","unstructured":"Sand\u00a0M, Bechara\u00a0FG, Gambichler\u00a0T, Sand\u00a0D, Friedlander\u00a0MR, Bromba\u00a0M et al (2016) Next-generation sequencing of the basal cell carcinoma miRNome and a\u00a0description of novel microRNA candidates under neoadjuvant vismodegib therapy: an integrative molecular and surgical case study. Ann Oncol 27(2):332\u2013338","journal-title":"Ann Oncol"},{"key":"1021_CR45","doi-asserted-by":"publisher","DOI":"10.1007\/s00347-019-0905-3","author":"L Boeckmann","year":"2019","unstructured":"Boeckmann\u00a0L, Martens\u00a0MC, Kakkassery\u00a0V, Heindl\u00a0LM, Emmert\u00a0S (2019) Molecular genetic investigations as the basis for targeted treatment of basal cell carcinoma of the eye. Ophthalmologe. https:\/\/doi.org\/10.1007\/s00347-019-0905-3","journal-title":"Ophthalmologe"},{"key":"1021_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2019.04.013","author":"M Eiger-Moscovich","year":"2019","unstructured":"Eiger-Moscovich\u00a0M, Reich\u00a0E, Tauber\u00a0G, Berliner\u00a0O, Priel\u00a0A, Simon\u00a0BG et al (2019) Efficacy of vismodegib for the treatment of orbital and advanced periocular basal cell carcinoma. Am J Ophthalmol. https:\/\/doi.org\/10.1016\/j.ajo.2019.04.013","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"1021_CR47","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/DSS.0000000000001640","volume":"45","author":"J Mathis","year":"2019","unstructured":"Mathis\u00a0J, Doerr\u00a0T, Lin\u00a0E, Ibrahim\u00a0SF (2019) Oral hedgehog pathway inhibition as a\u00a0means for ocular salvage in locally advanced Intraorbital basal cell carcinoma. Dermatol Surg 45(1):17\u201325","journal-title":"Dermatol Surg"},{"issue":"4","key":"1021_CR48","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/IOP.0000000000001251","volume":"35","author":"O Sagiv","year":"2019","unstructured":"Sagiv\u00a0O, Ding\u00a0S, Ferrarotto\u00a0R, Glisson\u00a0B, Altan\u00a0M, Johnson\u00a0F et\u00a0al (2019) Impact of food and drug administration approval of vismodegib on prevalence of orbital exenteration as a\u00a0necessary surgical treatment for locally advanced periocular basal cell carcinoma. Ophthalmic Plast Reconstr Surg 35(4):350\u2013353","journal-title":"Ophthalmic Plast. Reconstr. Surg."},{"key":"1021_CR49","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2147\/IMCRJ.S168666","volume":"11","author":"DT Hogarty","year":"2018","unstructured":"Hogarty\u00a0DT, Dewhurst\u00a0NG, Burt\u00a0B (2018) Vismodegib and orbital excision for treating locally advanced basal cell carcinoma. Int Med Case Rep\u00a0J 11:177\u2013179","journal-title":"Int Med Case Rep J"},{"issue":"3","key":"1021_CR50","doi-asserted-by":"crossref","first-page":"e394","DOI":"10.1097\/MJT.0000000000000721","volume":"25","author":"B Khalid","year":"2018","unstructured":"Khalid\u00a0B, Mukherjee\u00a0S, Ibrahimi\u00a0S, Cannon\u00a0T, Gilles\u00a0E, Moreau\u00a0A et\u00a0al (2018) Switching the smoothened inhibitor may have benefit in advanced basal cell carcinoma. Am J Ther 25(3):e394\u2013e6","journal-title":"Am J Ther"},{"issue":"4","key":"1021_CR51","doi-asserted-by":"crossref","first-page":"415","DOI":"10.4103\/0974-9233.167823","volume":"22","author":"K Gunduz","year":"2015","unstructured":"Gunduz\u00a0K, Yanik\u00a0O (2015) Myths in the diagnosis and management of orbital tumors. Middle East Afr J Ophthalmol 22(4):415\u2013420","journal-title":"Middle East Afr J Ophthalmol"},{"issue":"19","key":"1021_CR52","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck\u00a0M, Rodriguez-Abreu\u00a0D, Robinson\u00a0AG, Hui\u00a0R, Csoszi\u00a0T, Fulop\u00a0A et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N\u00a0Engl J Med 375(19):1823\u20131833","journal-title":"N Engl J Med"},{"issue":"1","key":"1021_CR53","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(16)30624-6","volume":"18","author":"MD Hellmann","year":"2017","unstructured":"Hellmann\u00a0MD, Rizvi\u00a0NA, Goldman\u00a0JW, Gettinger\u00a0SN, Borghaei\u00a0H, Brahmer\u00a0JR et al (2017) Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol 18(1):31\u201341","journal-title":"Lancet Oncol"},{"issue":"2","key":"1021_CR54","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"JD Wolchok","year":"2013","unstructured":"Wolchok\u00a0JD, Kluger\u00a0H, Callahan\u00a0MK, Postow\u00a0MA, Rizvi\u00a0NA, Lesokhin\u00a0AM et\u00a0al (2013) Nivolumab plus ipilimumab in advanced melanoma. N\u00a0Engl J Med 369(2):122\u2013133","journal-title":"N Engl J Med"},{"issue":"4","key":"1021_CR55","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber\u00a0JS, D\u2019Angelo\u00a0SP, Minor\u00a0D, Hodi\u00a0FS, Gutzmer\u00a0R, Neyns\u00a0B et al (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA\u20114 treatment (CheckMate 037): a\u00a0randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16(4):375\u2013384","journal-title":"Lancet Oncol"},{"issue":"1","key":"1021_CR56","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s40425-018-0439-2","volume":"6","author":"F Sabbatino","year":"2018","unstructured":"Sabbatino\u00a0F, Marra\u00a0A, Liguori\u00a0L, Scognamiglio\u00a0G, Fusciello\u00a0C, Botti\u00a0G et al (2018) Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a\u00a0case report and review of the literature. J\u00a0Immunother Cancer 6(1):126","journal-title":"J Immunother Cancer"},{"issue":"6","key":"1021_CR57","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1159\/000487084","volume":"41","author":"S Fischer","year":"2018","unstructured":"Fischer\u00a0S, Ali\u00a0HO, Jochum\u00a0W, Kluckert\u00a0T, Flatz\u00a0L, Siano\u00a0M (2018) Anti-PD\u20111 therapy leads to near-complete remission in a\u00a0patient with metastatic basal cell carcinoma. Oncol Res Treat 41(6):391\u2013394","journal-title":"Oncol Res Treat"},{"issue":"3","key":"1021_CR58","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jdcr.2018.01.015","volume":"4","author":"JGD Cannon","year":"2018","unstructured":"Cannon\u00a0JGD, Russell\u00a0JS, Kim\u00a0J, Chang\u00a0ALS (2018) A case of metastatic basal cell carcinoma treated with continuous PD\u20111 inhibitor exposure even after subsequent initiation of radiotherapy and surgery. JAAD Case Rep 4(3):248\u2013250","journal-title":"JAAD Case Rep"},{"key":"1021_CR59","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40425-017-0228-3","volume":"5","author":"EJ Lipson","year":"2017","unstructured":"Lipson\u00a0EJ, Lilo\u00a0MT, Ogurtsova\u00a0A, Esandrio\u00a0J, Xu\u00a0H, Brothers\u00a0P et al (2017) Basal cell carcinoma: PD-L1\/PD\u20111 checkpoint expression and tumor regression after PD\u20111 blockade. J\u00a0Immunother Cancer 5:23","journal-title":"J Immunother Cancer"},{"key":"1021_CR60","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s40425-016-0176-3","volume":"4","author":"GS Falchook","year":"2016","unstructured":"Falchook\u00a0GS, Leidner\u00a0R, Stankevich\u00a0E, Piening\u00a0B, Bifulco\u00a0C, Lowy\u00a0I et al (2016) Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810. J\u00a0Immunother Cancer 4:70","journal-title":"J Immunother Cancer"},{"issue":"8","key":"1021_CR61","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/CAD.0b013e32834618da","volume":"22","author":"U Reinhold","year":"2011","unstructured":"Reinhold\u00a0U (2011) Electrochemotherapy for primary skin cancer and skin metastasis related to other malignancies. Anticancer Drugs 22(8):711\u2013718","journal-title":"Anticancer Drugs"},{"issue":"4","key":"1021_CR62","first-page":"308","volume":"13","author":"A Kreuter","year":"2015","unstructured":"Kreuter\u00a0A, van Eijk\u00a0T, Lehmann\u00a0P, Fischer\u00a0M, Horn\u00a0T, Assaf\u00a0C et\u00a0al (2015) Electrochemotherapy in advanced skin tumors and cutaneous metastases\u2014a\u00a0retrospective multicenter analysis. J\u00a0Dtsch Dermatol Ges 13(4):308\u2013315","journal-title":"J Dtsch Dermatol Ges"},{"issue":"2","key":"1021_CR63","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s10549-016-4046-y","volume":"161","author":"MG Bourke","year":"2017","unstructured":"Bourke\u00a0MG, Salwa\u00a0SP, Sadadcharam\u00a0M, Whelan\u00a0MC, Forde\u00a0PF, Larkin\u00a0JO et al (2017) Effective treatment of intractable cutaneous metastases of breast cancer with electrochemotherapy: ten-year audit of single centre experience. Breast Cancer Res Treat 161(2):289\u2013297","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"1021_CR64","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1016\/j.ejso.2016.06.399","volume":"42","author":"LG Campana","year":"2016","unstructured":"Campana\u00a0LG, Testori\u00a0A, Curatolo\u00a0P, Quaglino\u00a0P, Mocellin\u00a0S, Framarini\u00a0M et al (2016) Treatment efficacy with electrochemotherapy: a multi-institutional prospective observational study on 376 patients with superficial tumors. Eur J Surg Oncol 42(12):1914\u20131923","journal-title":"Eur J Surg Oncol"},{"issue":"6","key":"1021_CR65","doi-asserted-by":"crossref","first-page":"648","DOI":"10.2340\/00015555-1361","volume":"92","author":"E Kis","year":"2012","unstructured":"Kis\u00a0E, Baltas\u00a0E, Kinyo\u00a0A, Varga\u00a0E, Nagy\u00a0N, Gyulai\u00a0R et al (2012) Successful treatment of multiple basaliomas with bleomycin-based electrochemotherapy: a\u00a0case series of three patients with Gorlin-Goltz syndrome. Acta Derm Venereol 92(6):648\u2013651","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"1021_CR66","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jaad.2003.11.066","volume":"50","author":"J Geisse","year":"2004","unstructured":"Geisse\u00a0J, Caro\u00a0I, Lindholm\u00a0J, Golitz\u00a0L, Stampone\u00a0P, Owens\u00a0M (2004) Imiquimod 5\u202f% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J\u00a0Am Acad Dermatol 50(5):722\u2013733","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1021_CR67","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S1470-2045(13)70530-8","volume":"15","author":"F Bath-Hextall","year":"2014","unstructured":"Bath-Hextall\u00a0F, Ozolins\u00a0M, Armstrong\u00a0SJ, Colver\u00a0GB, Perkins\u00a0W, Miller\u00a0PS et al (2014) Surgical excision versus imiquimod 5\u202f% cream for nodular and superficial basal-cell carcinoma (SINS): a\u00a0multicentre, non-inferiority, randomised controlled trial. Lancet Oncol 15(1):96\u2013105","journal-title":"Lancet Oncol"},{"issue":"3","key":"1021_CR68","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jid.2016.10.019","volume":"137","author":"HC Williams","year":"2017","unstructured":"Williams\u00a0HC, Bath-Hextall\u00a0F, Ozolins\u00a0M, Armstrong\u00a0SJ, Colver\u00a0GB, Perkins\u00a0W et al (2017) Surgery versus 5\u202f% Imiquimod for nodular and superficial basal cell carcinoma: 5\u2011year results of the SINS randomized controlled trial. J\u00a0Invest Dermatol 137(3):614\u2013619","journal-title":"J Invest Dermatol"},{"issue":"12","key":"1021_CR69","first-page":"1431","volume":"145","author":"WE Love","year":"2009","unstructured":"Love\u00a0WE, Bernhard\u00a0JD, Bordeaux\u00a0JS (2009) Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a\u00a0systematic review. Arch Dermatol 145(12):1431\u20131438","journal-title":"Arch Dermatol"},{"issue":"1","key":"1021_CR70","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0009-9260(86)80161-1","volume":"37","author":"VL Hall","year":"1986","unstructured":"Hall\u00a0VL, Leppard\u00a0BJ, McGill\u00a0J, Kesseler\u00a0ME, White\u00a0JE, Goodwin\u00a0P (1986) Treatment of basal-cell carcinoma: comparison of radiotherapy and cryotherapy. Clin Radiol 37(1):33\u201334","journal-title":"Clin Radiol"},{"issue":"3","key":"1021_CR71","first-page":"633","volume":"164","author":"JR Ramsay","year":"2011","unstructured":"Ramsay\u00a0JR, Suhrbier\u00a0A, Aylward\u00a0JH, Ogbourne\u00a0S, Cozzi\u00a0SJ, Poulsen\u00a0MG et\u00a0al (2011) The sap from Euphorbia peplus is effective against human nonmelanoma skin cancers. Br J Dermatol 164(3):633\u2013636","journal-title":"Br J Dermatol"},{"issue":"2","key":"1021_CR72","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1440-0960.2010.00626.x","volume":"51","author":"G Siller","year":"2010","unstructured":"Siller\u00a0G, Rosen\u00a0R, Freeman\u00a0M, Welburn\u00a0P, Katsamas\u00a0J, Ogbourne\u00a0SM (2010) PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a\u00a0randomized phase IIa trial. Australas J Dermatol 51(2):99\u2013105","journal-title":"Australas J Dermatol"},{"issue":"1","key":"1021_CR73","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jaad.2016.01.050","volume":"75","author":"T Brinkhuizen","year":"2016","unstructured":"Brinkhuizen\u00a0T, Frencken\u00a0KJ, Nelemans\u00a0PJ, Hoff\u00a0ML, Kelleners-Smeets\u00a0NW, Zur Hausen\u00a0A et al (2016) The effect of topical diclofenac 3\u202f% and calcitriol 3 mug\/g on superficial basal cell carcinoma (sBCC) and nodular basal cell carcinoma (nBCC): a phase II, randomized controlled trial. J\u00a0Am Acad Dermatol 75(1):126\u2013134","journal-title":"J Am Acad Dermatol"},{"issue":"17","key":"1021_CR74","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1056\/NEJMoa1506197","volume":"373","author":"AC Chen","year":"2015","unstructured":"Chen\u00a0AC, Martin\u00a0AJ, Choy\u00a0B, Fernandez-Penas\u00a0P, Dalziell\u00a0RA, McKenzie\u00a0CA et al (2015) A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. N\u00a0Engl J Med 373(17):1618\u20131626","journal-title":"N Engl J Med"},{"issue":"9","key":"1021_CR75","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/ijc.30630","volume":"140","author":"SM Park","year":"2017","unstructured":"Park\u00a0SM, Li\u00a0T, Wu\u00a0S, Li\u00a0WQ, Weinstock\u00a0M, Qureshi\u00a0AA et\u00a0al (2017) Niacin intake and risk of skin cancer in US women and men. Int J Cancer 140(9):2023\u20132031","journal-title":"Int J Cancer"},{"issue":"8","key":"1021_CR76","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1002\/cncr.26374","volume":"118","author":"KC Kadakia","year":"2012","unstructured":"Kadakia\u00a0KC, Barton\u00a0DL, Loprinzi\u00a0CL, Sloan\u00a0JA, Otley\u00a0CC, Diekmann\u00a0BB et al (2012) Randomized controlled trial of acitretin versus placebo in patients at high-risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251). Cancer 118(8):2128\u20132137","journal-title":"Cancer"}],"container-title":["Der Ophthalmologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-019-01021-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00347-019-01021-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-019-01021-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T01:09:23Z","timestamp":1607130563000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00347-019-01021-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,6]]},"references-count":76,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["1021"],"URL":"https:\/\/doi.org\/10.1007\/s00347-019-01021-4","relation":{},"ISSN":["0941-293X","1433-0423"],"issn-type":[{"value":"0941-293X","type":"print"},{"value":"1433-0423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,6]]},"assertion":[{"value":"6 December 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"V.\u00a0Kakkassery hat Vortragshonorare von der Firma Roche, Bayer, Allergan und Novartis sowie Beratungshonorare von der Firma Roche und Novartis erhalten. S.\u00a0Emmert, I.A.\u00a0Adamietz, G.\u00a0Kov\u00e1cs, A.M.\u00a0J\u00fcnemann, C.\u00a0Otte, M.\u00a0Zimbelmann, A.\u00a0Brosig, S.\u00a0Grisanti und L.M.\u00a0Heindl geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patienten zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}